IL2 and cancer: Moreover, we identify the depletion of Tregs, rather than the expansion of cytotoxic CD8+ T-cells and NK cells, as a major determinant for antitumour activity, providing important guidance for the future development of IL-2 reagents for cancer immunotherapy.